Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Dec 10, 2025 3:35 AM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
More on Gerson and Evangelical Politics
As a follow-up to John Armstrong’s post, I point you to this excellent response to Gerson’s article by Joe Knippenberg at No Left Turns (HT: Good Will Hinton). Knippenberg raises the relevant question whether “the ‘new evangelicals’ he describes will have sound practical judgment to go along with their decency and moral energy.” I think it’s true that the potential is there for the “new” evangelicals to go the Jim Wallis route, who is proclaiming the election as “a defeat...
A New Kind of Evangelical Presence
Pundits and pollsters are sorting out the results of Tuesday’s elections day-by-day now. Most are agreed that these mid-term elections do not signal a huge victory for the political left. But why? The Democrats did win both houses of Congress didn’t they? Most of the seats lost by Republicans were lost to candidates as a result of the Democrats running men and women who were far less extreme than the voices of the post-60s crowd that has controlled their party...
Chicken Little circa 2006
The UN has been busy updating the Chicken Little fable into a contemporary context. You know the story where the little chick runs around crying, “The sky is falling! The sky is falling!” In this edition, however, the looming disaster is (predictably) climate change. The es courtesy of the U.S. Senate Committee on Environment and Public Works (HT: NewsBusters). Sedna, the Mother of the Sea The Gaia motif is perhaps the most revealing part, as in “Tore and the Town...
Conservatives and the GOP
In an op-ed last week, Acton senior fellow Jerry Zandstra argues that in Michigan, even though the GOP lost, conservatives won. In “GOP loses, but conservatives win in Michigan” Zandstra explains the phenomenon that “Conservative positions won in the ballot initiatives but Republican candidates lost.” Some more evidence that Republicans have generally abandoned conservative economic es from Cato@Liberty’s examination of the voting records of ousted GOP lawmakers (HT: AmSpec Blog). The conclusion? “The great majority of losing Republicans were economic...
The Social Aspect of the Gospel
In preparing for the paper I’m giving this week on Bonhoeffer’s views of church and state, I ran across the following quotes, which nicely illustrate his view of the gospel and its relation to alleviation of social oppression and suffering. In his essay, “Ultimate and Penultimate Things,” he writes, It would be blasphemy against God and our neighbor to leave the hungry unfed while saying that God is closest to those in deepest need. We break bread with the hungry...
The Catholicity of the Reformation: Musings on Reason, Will, and Natural Law, Part 7
This post concludes my series on the largely forgotten catholicity of Protestant ethics, with a few brief remarks and reflections. My goal for this series, as stated in Part 1, was to show that voluntarism and nominalism are not the same thing, that two important Reformed theologians (Peter Martyr Vermigli and Jerome Zanchi) had more than a passing interest in Thomism (or intellectualism as Pope Benedict XVI referred to it in his now famous Regensburg address), and that evangelicals need...
Food for Thought: Andrew Sullivan and Retrofitted Christianity
The Hugh Hewitt/Andrew Sullivan kerfuffle has been mentioned a few times on the PowerBlog (here and here, for example), and while the dust has largely settled from that event, the issues that it raised continue to be addressed in various corners of the blogosphere. The most interesting (and mentary that I’ve read on Sullivan and his new book is by the Rev. Dr. Mark Roberts, who serves as Senior Pastor of Irvine Presbyterian Church in Irvine, California. Roberts’ critique is...
This Week at ETS
A number of us who are affiliated with the Acton Institute in various ways will be traveling to Washington, D.C. this week to attend the 58th annual meeting of the Evangelical Theological Society, “Christians in the Public Square.” I hope to bring you updates from some of the more interesting and engaging presentations. With that in mind, for your interest below are the papers scheduled to be given by Acton scholars: Wednesday, November 15 E. Calvin Beisner, “Scientific Orthodoxies, Politicized...
Catholic Social Teaching and Health Care
Susan Stabile, a law professor at St. John’s University and a contributor to Mirror of Justice, analyzes the current state of health coverage in the United States in light of Catholic social teaching in this article. I have quibbles here and there along the way, but on the whole the approach and the conclusions are sound. She is probably right that Health Savings Accounts (HSAs) have limited value, though my reasoning would be a little different. I would say that,...
Reflections on ETS Day One
Things were busy here yesterday at the annual meeting of the Evangelical Theological Society in Washington, D.C. With over 1800 registered attendees and 600+ papers being presented, the ideas are flying fast and furious. My paper on Bonhoeffer’s views of church and state went well. A few people asked me to send them copies of the paper, so expect a series of blog posts containing the text ing days (once I clean up the textual apparatus). One highlight of the...
Related Classification
Copyright 2023-2025 - www.mreligion.com All Rights Reserved